Editorial

Majority of Pediatric Patients with Hodgkin Lymphoma Achieve CR After Treatment with Brentuximab

Six out of nine pediatric patients with relapsed or refractory Hodgkin lymphoma (HL) (n=5)or systemic anaplastic large cell lymphoma...

European Medicines Agency Accepts Brentuximab Marketing Authorization Application

European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for brentuximab vedotin (Adcetris™, Takeda...

Novel Drugs Breaks Down Barriers – Attacks Breast Cancer Cells from Inside Out

Throwing stones at castle walls is one way to attack an enemy, but sneaking inside makes the target much...

Sanofi-Aventis In-licenses Therapeutic Antibody for the Treatment of Solid Cancers From Oxford BioTherapeutics’ –...

Earlier this month French pharmaceutical giant Sanofi-aventis acquired an exclusive world-wide license to one of Oxford BioTherapeutics’ internal preclinical...

Pfizer and Seattle Genetics Agree on Antibody-Drug Conjugate Collaboration

Pfizer and Seattle Genetics, a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for...

Brentuximab Offers Promising New Treatment Option for Patients with Relapsed or Refractory HL and...

While 70 to 80% of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy...

Phase I Trial of Loaded Antibody Establishes Dose, Catalogues Side Effects and Hints at...

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or...

Pivotal Trial In Relapsed And Refractory Hodgkin Lymphoma Shows Positive Results With Brentuximab Vedotin...

Results of a pivotal clinical trial with of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30...

FDA Rejects Accelerated Approval For T-DM1, Global Regulatory Submission Expected In Mid 2012

Earlier today the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for...

Investigational Antibody-Drug Conjugate, Shows Encouraging Results in Women With Highly Advanced HER2-positive Breast Cancer

Results of a Phase II study of trastuzumab (Herceptin®, Genentech) in combination with DM1 (T-DM1), an investigational HER2 antibody-drug...

FEATURED RESOURCES